Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. Jan-Dec 2020;14:1753466620926853.
doi: 10.1177/1753466620926853.

Potential Specific Therapies in COVID-19

Affiliations
Free PMC article
Review

Potential Specific Therapies in COVID-19

Muhammad Hamdan Gul et al. Ther Adv Respir Dis. .
Free PMC article

Abstract

COVID-19 has grown into a global pandemic that has strained healthcare throughout the world. There is a sense of urgency in finding a cure for this deadly virus. In this study, we reviewed the empiric options used in common practice for COVID-19, based on the literature available online, with an emphasis on human experiences with these treatments on severe acute respiratory syndrome-associated coronavirus (SARS-COV-1) and other viruses. Convalescent blood products are the most promising potential treatment for use in COVID-19. The use of chloroquine or hydroxychloroquine (HCQ), remdesivir, and tocilizumab are some of the other promising potential therapies; however, they are yet to be tested in randomized clinical trials (RCTs). The use of lopinavir-ritonavir did not prove beneficial in a large RCT. The use of corticosteroids should be avoided in COVID-19 pneumonia unless used for other indications, based on the suggestion of harm in patients with SARS-COV-1 and Middle Eastern Respiratory Syndrome (MERS) infection. The reviews of this paper are available via the supplemental material section.

Keywords: IL-6; MERS; SARS-COV-1; convalescent blood products; coronavirus; corticosteroids convalescent sera; favipiravir; interferons; lopinavir-ritonavir; novel virus; remdesivir; ribavirin; tocilizumab.

Conflict of interest statement

Conflict of interest statement: The authors declare that there is no conflict of interest.

Similar articles

See all similar articles

References

    1. Zhou P, Yang X-L, Wang X-G, et al. Discovery of a novel coronavirus associated with the recent pneumonia outbreak in humans and its potential bat origin. bioRxiv 2020. DOI: 10.1101/2020.01.22.914952. - DOI
    1. Luke TC, Kilbane EM, Jackson JL, et al. Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment? Ann Intern Med 2006; 145: 599–609. - PubMed
    1. Mair-Jenkins J, Saavedra-Campos M, Baillie JK, et al. The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis. J Infect Dis 2014; 211: 80–90. - PMC - PubMed
    1. van Griensven J, Edwards T, de Lamballerie X, et al. Evaluation of convalescent plasma for Ebola virus disease in Guinea. N Engl J Med 2016; 374: 33–42. - PMC - PubMed
    1. Mulangu S, Dodd LE, Davey RT, Jr, et al. A randomized, controlled trial of Ebola virus disease therapeutics. N Engl J Med 2019; 381: 2293–2303. - PubMed

MeSH terms

Substances

Supplementary concepts

Feedback